INX-08189

DRUG3 trials

Sponsors

Bristol-Myers Squibb

Conditions

HCV (Genotype 1)HealthyHepatitis C

Phase 1

A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy Subjects

CompletedNCT01159808

Bristol-Myers SquibbHealthy

Start: 2010-05-31End: 2010-10-31Updated: 2012-06-22

Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects

CompletedNCT01250366

Bristol-Myers SquibbHCV (Genotype 1)

Start: 2010-10-31End: 2011-06-30Updated: 2012-07-12

Phase 2

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

TerminatedNCT01425970

Bristol-Myers SquibbHepatitis C

Start: 2012-05-31End: 2013-08-31Updated: 2015-11-04